JPS6122865A - Replenishing solution for artificial kidney apparatus - Google Patents
Replenishing solution for artificial kidney apparatusInfo
- Publication number
- JPS6122865A JPS6122865A JP59145107A JP14510784A JPS6122865A JP S6122865 A JPS6122865 A JP S6122865A JP 59145107 A JP59145107 A JP 59145107A JP 14510784 A JP14510784 A JP 14510784A JP S6122865 A JPS6122865 A JP S6122865A
- Authority
- JP
- Japan
- Prior art keywords
- liter
- artificial kidney
- solution
- replacement fluid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- External Artificial Organs (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
〈産業−１−の利用分野〉
本発明は、大量の補液を行ないながら濾過液を得て、“
血液から老廃物（尿毒素物質）を除去する濾過聖人、１
−腎臓用の補液に関するものである。[Detailed Description of the Invention] <Field of Application in Industry-1-> The present invention obtains a filtrate while performing a large amount of fluid replacement.
A filtration saint who removes waste products (uremic toxins) from the blood, 1
- Concerning renal replacement fluids.
〈従来技術〉
従来、慢性腎不全患者の一般的治療法及びその生命延長
法として主として拡散により血液から老廃物及び水分を
透析液側に除去して腎臓の代りをする手段である透析型
人工腎臓が普及している。<Prior art> Conventionally, as a general treatment for chronic renal failure patients and a life extension method, dialysis-type artificial kidneys are a means of removing waste products and water from the blood to the dialysate side mainly by diffusion to replace the kidneys. is widespread.
ところが、血液透析型の人工腎臓は、１回の治療に２０
０ □〜３０６リットルの透析液を４〜６時間を要して
使用し、しかも血圧降下や気分不良等の症状が副作用と
して頻発しこのような副作用の影響が大きい症状の患者
には血液透析型に代わるものとして、濾過型人工腎臓に
よる治療が試みられるようになった。これは、近年、水
の透過性か極めて良好な膜が開発されたことにより、腎
臓の糸球体で濾過により血液から凍原が作り出されるの
と同じように、大量の補液を行ないなから濾過液を得て
老廃物を除去する方法で、膜を通しで水の流れに伴って
物質が移動するため、膜を通過する物質であれば分子量
の大きさにあまり左右されずに物質が除去される特徴が
あり、前記拡散の原理による透析型では、尿素やクレア
チニン等の分子量の小さい物質の除去は容易でも、分子
量が大きくなるにつれてその物質の除去に制限、限度が
あったが濾過型にはこのような欠点がない。However, a hemodialysis type artificial kidney requires 20
0 □~306 liters of dialysate is used over a period of 4~6 hours, and symptoms such as a drop in blood pressure and poor mood occur frequently as side effects.Hemodialysis type is recommended for patients with symptoms where such side effects have a large impact. As an alternative treatment, attempts have been made to use filtering artificial kidneys. In recent years, membranes with extremely high water permeability have been developed, and in the same way that frozen ground is created from blood through filtration in the glomerulus of the kidney, filtrate is removed without replacing large amounts of fluid. This method removes waste products by removing waste products, and since the substances move with the flow of water through the membrane, if the substance passes through the membrane, it is removed without being greatly influenced by the size of its molecular weight. With the dialysis type, which uses the principle of diffusion, it is easy to remove substances with small molecular weights such as urea and creatinine, but as the molecular weight increases, there are limits to the removal of such substances. There are no drawbacks.
又、該濾過型、透析型の長所をとり入れた濾過透析型人
工腎臓も、現今、透析型の改良方式として用いられてい
る。Furthermore, a filtration and dialysis type artificial kidney that incorporates the advantages of the filtration type and dialysis type is currently being used as an improved method of the dialysis type.
これら濾過聖人］二腎臓では、１回５時ｎ１ｌｉこ２０
１Ｊツトル乃至２５リットル（透析・濾過型で４〜５リ
ットル）の血液の濾過が可能で、それに見合う補液を行
ない乍ら濾液を得るもので、適切な組成の該補液を、血
液濾過を行なうためのフィルターの手前で注入する前希
釈法又は、フィルターの後の静脈側から注入する後希釈
法により注入する。These filter saints] With two kidneys, once 5 o'clock n1li this 20
It is possible to filter 1 J to 25 liters of blood (4 to 5 liters for dialysis/filtration type), and obtains filtrate while replacing fluid corresponding to that amount.The replacement fluid with an appropriate composition is used for blood filtration. Inject by pre-dilution method, injecting before the filter, or post-dilution method, injecting from the venous side after the filter.
該補液は、直接血液中に入るため、血漿の組成に大きな
変動を与えない組成が必要で、Ｎａ”＋Ｋ”Ｃａ４４
、 Ｎ４ ｇ＋＋、の陽イオンの適切な濃度及び血液の
緩衝剤（アルカリ化剤）に関し、種々の改善、配慮がな
され、現在市販されている人工腎臓用補液は、緩衝剤と
し、て酢酸塩又は乳酸塩が用いられている。Since the replacement fluid enters directly into the blood, it must have a composition that does not cause large fluctuations in the plasma composition, and must have a composition that does not cause large changes in the plasma composition.
Various improvements and considerations have been made regarding the appropriate concentration of cations such as , N4 g++, and blood buffering agents (alkalinizing agents), and the artificial kidney replacement fluids currently on the market contain acetate or Lactate is used.
これらの緩衝剤は、体内で代謝され、人体体液の本来の
緩衝剤である重炭酸となって緩衝作用をする。ところが
、重症患者にあってはこれら酢酸塩又は乳酸塩°を含む
補液では治療中の血圧降下や気分不良等が頻発し、安定
した治療を行ない難いという問題かあり、酢酸塩及び乳
酸塩に代り重炭酸を配合した補液が要望されているが、
重炭酸を配合した場合、時間の経過とともに補液中のＣ
ａ（カルシラｌ、）及びＭｇ（マグネシウム）と反応し
、不溶性の沈澱を生し治療に用いられないという重大な
欠点かある！、−め、使用直前に配合し混入、調整しで
使用するＡ 、Ｂ （又はＬｍの個別の２液型としてい
る１１重炭酸を配合する該２液型の補液としては、従来
、
Ａ液；塩化ナトリウム、塩化カリウム、塩化カルシウム
、塩化マグネシウム及びブドウ糖、Ｂ液；炭酸水素ナト
リウムを含有したもの。These buffering agents are metabolized in the body and become bicarbonate, which is a natural buffering agent for human body fluids, and has a buffering effect. However, for critically ill patients, these fluid replacement fluids containing acetate or lactate often cause a drop in blood pressure or poor mood during treatment, making it difficult to provide stable treatment. There is a demand for replacement fluids containing bicarbonate,
When bicarbonate is added, C in the replacement fluid decreases over time.
It has a serious drawback in that it reacts with a (calcylalyl) and Mg (magnesium) and forms an insoluble precipitate, making it unusable for treatment! Conventionally, the two-component replacement fluid containing bicarbonate has been conventionally used as a two-component replacement fluid of A and B (or Lm), which are mixed and adjusted immediately before use. Contains sodium chloride, potassium chloride, calcium chloride, magnesium chloride and glucose, Solution B; sodium hydrogen carbonate.
で、その混合比率による２種類の補液が知られ、その１
はＡ液が電解質を主体とし、Ｂ液は重炭酸ナトリウムの
みのものでＡ：Ｂが４ ： １ （１００：２５）、そ
の２は、Ａ液：Ｂ液が９ ： １ （９０：１０）で、
その１例として、Ａ液は理論値、
Ｎａ” １３６ｏ＋Ｅｑ／リツ）ルＣａ”
４＋２．０〜３．０ｍＥｑ／リットルＭｇ“
１，５ｍＥｑ／リットルＣＩ−］］５ｍＥｑ／リッ
トルＨＣＯ； ３２＋２．０〜３．０ｍＥｑ／リ
ットルグルコ一ス２８３ｍＥｑ／ｃｌリットルで、Ｃ０
２ガスで封入した該Ａ液９００ｃｃと、ｂｉｃａｒ−ｌ
〕ｏ＋＋ａｔｅ−炭酸水素ナトリウムＮａＨＣＯ３入り
Ｂ液］００ｃｃとして両方ともにＢ液の比率が比較的高
い。Two types of replacement fluids are known depending on the mixing ratio, and the first one is
The A solution is mainly electrolyte, and the B solution is only sodium bicarbonate, with A:B ratio of 4:1 (100:25), and the second solution is A:B solution: 9:1 (90:10). in,
As an example, the theoretical value of liquid A is Na" 136o + Eq/Lit (Ca)
4+2.0~3.0mEq/liter Mg"
1,5 mEq/liter CI-]]5 mEq/liter HCO; 32+2.0-3.0 mEq/liter glucose 283 mEq/cl liter, C0
900cc of liquid A sealed with two gases and bicar-l
[o++ate-B solution containing sodium bicarbonate, NaHCO3] As 00 cc, the proportion of B solution is relatively high in both cases.
そこで使用に際し、正確な計量、十分な均質混合回路に
組入れる繰作には専用の機械装置（Ａ液、Ｂ液の吐出量
が夫々４：１の割合に設定された２つのローラーポンプ
で両液をバランスさせる）必要があった。Therefore, during use, a special mechanical device (two roller pumps with a discharge rate of 4:1 for liquids A and B, respectively) is used to accurately measure and assemble the mixture into a sufficiently homogeneous mixing circuit. balance) was necessary.
〈発明が解決しようとする問題点〉
本発明の補液は、」二記従来の補液のＡ、Ｂの混合比率
では使用前の操作及び装置を要する欠点を改善し、専門
機や専門家を要することのない補液を提供しようとする
ものである。<Problems to be Solved by the Invention> The replacement fluid of the present invention improves the disadvantages of the mixing ratio of A and B of the conventional replacement fluid described in section 2, which requires operations and equipment before use, and eliminates the need for specialized machines and experts. The aim is to provide a never-ending supply of fluids.
〈問題点を解決するための手段〉
本発明の重炭酸を配合した２液型の人工腎臓用補液は、
Ａ液とＢ液の混合比率を１００： １〜２とすることに
１こって専用装置や混合操作の困難さを排除して手繰作
で容易に使用し得ることを特徴とし、Ａ液は、塩化ナト
リウム（ＮａＣｌ）、塩化カリウム（ＫＣｌ）、炭酸水
素ナトリウム（ＮａＨＣＯ＝）、Ｂ液は、塩化カルシウ
ム（ＣａＣ１２・２Ｈ２０）、塩化マグネシウム（Ｍ
ｉ！ Ｃト・６Ｈ２０）及び少量の緩衝剤として氷酢酸
（ＣＩｌ、Ｃ００Ｉ−ｆ）を使用して成るものであり、
治療に際し、所定電解質濃度に混合調整する。尚、必要
に応じＢ液にブドウ糖を添加してもよい。該Ａ、１３両
液の電解質濃度は、下記の通りである。<Means for solving the problems> The two-component artificial kidney replacement fluid containing bicarbonate of the present invention is as follows:
The mixing ratio of liquid A and liquid B is 100:1 to 2, which eliminates the need for specialized equipment and the difficulty of mixing operations, making it easy to use by hand. Sodium chloride (NaCl), potassium chloride (KCl), sodium hydrogen carbonate (NaHCO=), liquid B contains calcium chloride (CaC12・2H20), magnesium chloride (M
i! 6H20) and a small amount of glacial acetic acid (CIl, C00I-f) as a buffer,
During treatment, mix and adjust the electrolyte concentration to a specified level. Incidentally, glucose may be added to the B solution if necessary. The electrolyte concentrations of both solutions A and 13 are as follows.
Ｎａ＋ （＋２．０〜３．０ｍＥｑ／リットル）
１３５〜１４５Ｋ” （ｍＥｑ／リットル）
２．０−３．０ＣＸ” （ｍＥｑ／リット
ル） ２．５〜４．ＯＭｇ” （ｍＥｑ／リ
ットル） ０．５〜１．５ＣＩ”−（ｍＥＱ／
リットル） １１０−１２０ＨＣＯ；（ｍＥｑ
／リットル） ２５〜３５グルコース（＋ｎｇ
／ｄリットル） ０〜２００ＰＨ； ７．２〜７
．５滲透正比 ；０．９〜１．０
〈実施例〉
本発明の実施例の詳細は下記に示す通りである。Na+ (+2.0-3.0mEq/liter)
135-145K” (mEq/liter)
2.0-3.0CX" (mEq/liter) 2.5-4.OMg" (mEq/liter) 0.5-1.5CI"-(mEQ/
liter) 110-120HCO; (mEq
/liter) 25-35 glucose (+ng
/d liter) 0-200PH; 7.2-7
．． 5 Transmission specific ratio; 0.9 to 1.0 <Examples> Details of examples of the present invention are as shown below.
実施例１
実施例２
尚、実施例１のＢ液のｐＨは３．５〜４．０に実施例２
の１３液のｐ Ｈは３．２〜３．７に夫々調整されてい
る。Example 1 Example 2 The pH of solution B in Example 1 was adjusted to 3.5 to 4.0 in Example 2.
The pH of each of the 13 solutions was adjusted to 3.2 to 3.7.
又；実施例１及び２ともＡ液１リットルに対してＢ液は
１０ｍ１であり、混合比率が１００：１のものを示す。Also, in both Examples 1 and 2, the amount of liquid B was 10 ml per liter of liquid A, and the mixing ratio was 100:1.
実施例３
実施例４
尚、実施例３のＢ液のｐＨは３．５〜４．０に実施例４
のＢ液の１市は３．２〜３．７に夫々調整されている。Example 3 Example 4 The pH of solution B of Example 3 was adjusted to 3.5 to 4.0 in Example 4.
One part of liquid B is adjusted to 3.2 to 3.7, respectively.
又、実施例：）及び４ともＡ液１リットルに対してＢ液
は２０＋ｎｌであり、混合比率が１００：２のものを示
す。In addition, in Examples 2 and 4, the amount of liquid B was 20+nl per liter of liquid A, and the mixing ratio was 100:2.
鳴り使用に際しては、Ａ液は１［リットル１バイアル瓶
、１３液は１０［ｍリットルｊ又は２０［ｍリットル１
のバイアル瓶の製品とし、使用直前にＢ液をＡ液に混合
１−で点滴注入するものであり、投与速度、投与時１１
１１及び投与量は前記従来の２液タイプのものと同様と
する。When using, liquid A should be in a 1 [liter 1 vial bottle, and liquid 13 should be in a 10 [ml j or 20 [ml 1] bottle.
It is a product in a vial bottle, and is injected as an infusion by mixing liquid B with liquid A immediately before use.
11 and the dosage are the same as those for the conventional two-liquid type.
〈発明の効果〉
以−１−のように本発明は、従来の補液が使用前に特別
な操作及び装置を必要とするのに対し、補液の混合比率
を変えることで専用機や専門家を要することなく、簡単
な手操作で補液を行ｒ（ｙ、ｒ得るという特有の効果を
奏する。<Effects of the Invention> As described in -1- below, while conventional replacement fluids require special operations and equipment before use, the present invention can change the mixing ratio of replacement fluids without requiring special equipment or specialists. It has the unique effect of performing fluid replacement and obtaining r(y,r) with a simple manual operation without the need for replenishment.
Claims (1)
、Ｋ＾＋、Ｃａ＾＋＾＋、Ｍｇ＾＋＾＋、Ｃｌ＾−及び
ＨＣＯ＿３＾−イオンから成る電解質イオンが一定比率
で含有されるよう各原料化合物を配合して成り、血液浄
化法による腎不全治療に際し、使用直前に混合されるＡ
、Ｂ２種の液の混合比率を１００：１〜２に配合したこ
とを特徴とする人工腎臓用補液。 ２、Ａ液の組成が塩化ナトリウム、塩化カリウム、炭酸
水素ナトリウム、Ｂ液の組成が塩化カルシウム、塩化マ
グネシウムである特許請求の範囲第１項記載の人工腎臓
用補液。 ３、電解質イオン組成が、Ｎａ＾＋１３５〜１４５ｍＥ
ｑ／リットル、Ｋ＾＋２．０〜３．０ｍＥｑ／リットル
、Ｃａ＾＋＾＋２．５〜４．０ｍＥｑ／リットル、Ｍｇ
＾＋＾＋０．５〜１．５ｍＥｑ／リットル、Ｃｌ＾−１
１０〜１２０ｍＥｑ／リットル、ＨＣＯ＿３＾−２５〜
３５ｍＥｑ／リットルである特許請求の範囲第１項記載
の人工腎臓用補液。[Claims] 1. Contains bicarbonate as a blood alkalizing agent, and contains Na^+
, K^+, Ca^+^+, Mg^+^+, Cl^- and HCO_3^- ions, each raw material compound is blended so that they are contained in a certain ratio, and the blood purification method is used. A mixed immediately before use for renal failure treatment
A replacement fluid for an artificial kidney, characterized in that the mixing ratio of two kinds of fluids B is 100:1 to 2. 2. The replacement fluid for an artificial kidney according to claim 1, wherein the composition of solution A is sodium chloride, potassium chloride, and sodium hydrogen carbonate, and the composition of solution B is calcium chloride and magnesium chloride. 3. Electrolyte ion composition is Na^+135~145mE
q/liter, K^+2.0~3.0mEq/liter, Ca^+^+2.5~4.0mEq/liter, Mg
^+^+0.5-1.5mEq/liter, Cl^-1
10~120mEq/liter, HCO_3^-25~
The artificial kidney replacement fluid according to claim 1, which has a concentration of 35 mEq/liter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59145107A JPS6122865A (en) | 1984-07-11 | 1984-07-11 | Replenishing solution for artificial kidney apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59145107A JPS6122865A (en) | 1984-07-11 | 1984-07-11 | Replenishing solution for artificial kidney apparatus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6122865A true JPS6122865A (en) | 1986-01-31 |
Family
ID=15377538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59145107A Pending JPS6122865A (en) | 1984-07-11 | 1984-07-11 | Replenishing solution for artificial kidney apparatus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6122865A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08181298A (en) * | 1995-07-27 | 1996-07-12 | Olympus Optical Co Ltd | Solid-state image pickup device |
| JPH0984853A (en) * | 1995-09-22 | 1997-03-31 | Material Eng Tech Lab Inc | Medical container holding organ preservation liquid |
| JP2006341113A (en) * | 2003-06-16 | 2006-12-21 | Fuso Pharmaceutical Industries Ltd | Medical fluid used by being mixed and having improved safety |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5620511A (en) * | 1979-07-24 | 1981-02-26 | Gambro Dialysatoren | Concentrated aqueous solution for dialysis solution |
| JPS5788116A (en) * | 1980-11-21 | 1982-06-01 | Tomita Seiyaku Kk | Preparation of mixed powder of electrolytic compound for bicarbonate dialysis |
| JPS58134016A (en) * | 1982-01-29 | 1983-08-10 | プレストン・レオナ−ド・ヴエルトマン | Dialytic solution containing hydrogencarbonate ion and manufacture |
-
1984
- 1984-07-11 JP JP59145107A patent/JPS6122865A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5620511A (en) * | 1979-07-24 | 1981-02-26 | Gambro Dialysatoren | Concentrated aqueous solution for dialysis solution |
| JPS5788116A (en) * | 1980-11-21 | 1982-06-01 | Tomita Seiyaku Kk | Preparation of mixed powder of electrolytic compound for bicarbonate dialysis |
| JPS58134016A (en) * | 1982-01-29 | 1983-08-10 | プレストン・レオナ−ド・ヴエルトマン | Dialytic solution containing hydrogencarbonate ion and manufacture |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08181298A (en) * | 1995-07-27 | 1996-07-12 | Olympus Optical Co Ltd | Solid-state image pickup device |
| JPH0984853A (en) * | 1995-09-22 | 1997-03-31 | Material Eng Tech Lab Inc | Medical container holding organ preservation liquid |
| JP2006341113A (en) * | 2003-06-16 | 2006-12-21 | Fuso Pharmaceutical Industries Ltd | Medical fluid used by being mixed and having improved safety |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5632897A (en) | Method for removing aluminum ions from blood | |
| US6123847A (en) | Device and process for regulating the sodium concentration in a dialysis liquid with a view to a prescription | |
| US4308255A (en) | Balanced oncotic pressure fluid | |
| DeSoi et al. | Phosphate kinetics during high-flux hemodialysis. | |
| Lanese et al. | Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers | |
| CA2757082C (en) | A multipart fluid system and a system for regional citrate anticoagulation in an extracorporeal blood circuit | |
| EP1176969B1 (en) | Substitution infusion fluid and citrate anticoagulation | |
| CA2440455A1 (en) | Bicarbonate-based solutions for dialysis therapies | |
| US5112622A (en) | Intravenous solutions for influencing renal function and for maintenance therapy | |
| ES2298125T3 (en) | HEMOFILTRATION DEVICE. | |
| Chanard et al. | Long‐term results of dialysis therapy with a highly permeable membrane | |
| WO2010112570A1 (en) | Dialysis solution | |
| Giovannetti et al. | Dialysis of methylguanidine | |
| WO2010112547A1 (en) | Dialysis precursor composition | |
| Quellhorst et al. | Hemofiltration: treatment of renal failure by ultrafiltration and substitution | |
| JPS58116362A (en) | Adsorbent composition for blood dialysis | |
| Ding et al. | Online hemodiafiltration versus acetate‐free biofiltration: a prospective crossover study | |
| JPS6122865A (en) | Replenishing solution for artificial kidney apparatus | |
| Choyke et al. | Clearance of gadolinium chelates by hemodialysis: an in vitro study | |
| Ing et al. | Fluid removal with negative-pressure hydrostatic ultrafiltration using a partial vacuum | |
| Santoro et al. | Acetate‐free biofiltration: a viable alternative to bicarbonate dialysis | |
| Albouze et al. | Urea rebound and residual renal function in the calculation of Kt/V and protein catabolic rate. | |
| JP6425661B2 (en) | Dialysis composition | |
| HUT68062A (en) | Method and liquids includiug hydrochloric acid for hemodialysis, and concentrate of two container for hemodialysing equipment | |
| Addae et al. | Glutamine balance in metabolic acidosis as studied with the artificial kidney |